Tags

Type your tag names separated by a space and hit enter

Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.

Abstract

High-risk human papillomavirus (hrHPV) testing has become an integral component of cervical cancer screening, given that persistent infection with hrHPV was recognized as a significant risk factor for most precancers and cancers of the cervix. Particularly, testing for hrHPV types (in conjunction with cervical cytology) has been approved for primary screening in women over 30 years of age and for cost-effective triaging of equivocal cervical cytology results. HPV was a small double-stranded DNA virus that cannot be cultured in vitro; so, different types of tests have been developed to detect its presence. Various molecular techniques were available for detecting the presence and/or quantity of hrHPV. In this review, the testing options for hrHPV and its surrogates, with an emphasis on those approved by the US Food and Drug Administration (FDA), were detailed. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    James Homer Wright Laboratory of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. hnishino@partners.org

    ,

    Source

    Cancer cytopathology 119:4 2011 Aug 25 pg 219-27

    MeSH

    Early Detection of Cancer
    Female
    Humans
    Papillomaviridae
    Papillomavirus Infections
    Uterine Cervical Neoplasms
    Vaginal Smears

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    21717588

    Citation

    Nishino, Ha Thanh, et al. "Testing for Human Papillomavirus in Cervical Cancer Screening: a Review of Indications and Methodology." Cancer Cytopathology, vol. 119, no. 4, 2011, pp. 219-27.
    Nishino HT, Tambouret RH, Wilbur DC. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Cancer Cytopathol. 2011;119(4):219-27.
    Nishino, H. T., Tambouret, R. H., & Wilbur, D. C. (2011). Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Cancer Cytopathology, 119(4), pp. 219-27. doi:10.1002/cncy.20161.
    Nishino HT, Tambouret RH, Wilbur DC. Testing for Human Papillomavirus in Cervical Cancer Screening: a Review of Indications and Methodology. Cancer Cytopathol. 2011 Aug 25;119(4):219-27. PubMed PMID: 21717588.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. AU - Nishino,Ha Thanh, AU - Tambouret,Rosemary H, AU - Wilbur,David C, Y1 - 2011/06/29/ PY - 2010/03/21/accepted PY - 2011/01/24/received PY - 2011/03/18/revised PY - 2011/7/1/entrez PY - 2011/7/1/pubmed PY - 2011/10/14/medline SP - 219 EP - 27 JF - Cancer cytopathology JO - Cancer Cytopathol VL - 119 IS - 4 N2 - High-risk human papillomavirus (hrHPV) testing has become an integral component of cervical cancer screening, given that persistent infection with hrHPV was recognized as a significant risk factor for most precancers and cancers of the cervix. Particularly, testing for hrHPV types (in conjunction with cervical cytology) has been approved for primary screening in women over 30 years of age and for cost-effective triaging of equivocal cervical cytology results. HPV was a small double-stranded DNA virus that cannot be cultured in vitro; so, different types of tests have been developed to detect its presence. Various molecular techniques were available for detecting the presence and/or quantity of hrHPV. In this review, the testing options for hrHPV and its surrogates, with an emphasis on those approved by the US Food and Drug Administration (FDA), were detailed. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society. SN - 1934-6638 UR - https://www.unboundmedicine.com/medline/citation/21717588/Testing_for_human_papillomavirus_in_cervical_cancer_screening:_a_review_of_indications_and_methodology_ L2 - https://doi.org/10.1002/cncy.20161 DB - PRIME DP - Unbound Medicine ER -